Display Settings:

Format

Send to:

Choose Destination

    Vaccine. 2006 Jan 12;24(2):151-6. Epub 2005 Aug 10.

    Assessment of the safety of a third dose of pneumococcal polysaccharide vaccine in the Vaccine Safety Datalink population.

    Jackson LA, Nelson JC, Whitney CG, Neuzil KM, Benson P, Malais D, Baggs J, Mullooly J, Black S, Shay DK.

    Center for Health Studies, 1730 Minor Ave, Ste 1600, Seattle, WA 98101, USA. jackson.l@ghc.org

    There is little information on the safety of administration of a third dose of pneumococcal polysaccharide vaccine (PPV). The authors conducted a retrospective assessment of 316,995 adult members of three health maintenance organizations who had received one, two, or three PPV doses. Medical encounters associated with diagnosis codes potentially indicative of an injection site reaction in the week following a first, second, or third PPV dose were identified. These presumptive events occurred in 0.3% (911/279504) of the first PPV group, 0.7% (257/36888) of the second PPV group, and 0.5% (3/603) of the third PPV group (p>0.5 for both comparisons with the third PPV group). These findings do not suggest that a third PPV dose is associated with an increased risk of medically attended injection site reactions compared with a first or second PPV dose.

    PMID: 16122845 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Pneumococcal Polysaccharide Vaccine (Pneumovax® 23)

      Pneumococcal disease is caused byStreptococcus pneumoniae bacteria. It is a leading cause of vaccine-preventable illness and death in the United States. Anyone can get pneumococcal disease, but some people are at greater...